Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of WD-1603 in Healthy Subjects (Fed Conditions)
NCT04591535Phase 1Unknown
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carbidopa and levodopa in Parkinson's disease (PD) (4 arms), sponsored by Shanghai WD Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 2 and Area Under the Curve at Day 2. Status: unknown.
02
Drugs
carbidopalevodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04591535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591535.